<unk>  must not be combined with strong inducers (i.e. activators) of the liver enzymes CYP3A4/5 if it can be avoided, as serious cases of liver toxicity have been observed under combination with the CYP3A4/5 inducer rifampicin.
Lorlatinib
Tucatinib
Neratinib
Fostamatinib
Lapatinib
Ponatinib
Brigatinib
Selpercatinib